Biofrontera director granted 20,000 stock options

Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock.

Rhea-AI Filing Summary

Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.

According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Weber Kevin Daniel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	20,000	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 20,000 contracts (Direct)

Footnotes (2)

1. F1. The option vests in twelve equal monthly installments beginning on April 4, 2026.
2. F2. Options with different terms are not included.

FAQ

What insider transaction did Biofrontera (BFRI) report for Kevin Daniel Weber?

Biofrontera reported that director Kevin Daniel Weber received an employee stock option grant for 20,000 shares at an exercise price of $0.00 per share. This award is reported as a derivative security and increases his directly held options by the same amount.

How many options were granted to the Biofrontera (BFRI) director in this Form 4?

The Form 4 shows a grant of employee stock options covering 20,000 shares of Biofrontera Inc. common stock. These options are recorded as a derivative security, with 20,000 options shown as directly owned following the transaction reported on March 4, 2026.

What is the exercise price of the Biofrontera (BFRI) options granted to Kevin Daniel Weber?

The employee stock options granted to Kevin Daniel Weber have an exercise price of $0.00 per share. This means he does not pay an exercise price to acquire shares upon exercise, subject to the vesting schedule and any other applicable plan or award terms.

When do the newly granted Biofrontera (BFRI) options begin vesting?

The options begin vesting on April 4, 2026. The grant vests in twelve equal monthly installments starting on that date, so portions of the 20,000 options become exercisable each month over approximately one year, as described in the filing footnote.

Over what period do Kevin Daniel Weber’s Biofrontera (BFRI) options vest?

The options vest over a twelve-month period. According to the disclosure, vesting occurs in twelve equal monthly installments beginning on April 4, 2026, resulting in a gradual vesting schedule rather than immediate full exercisability of the 20,000-share option grant.

Does the Biofrontera (BFRI) Form 4 include other options held by Kevin Daniel Weber?

The Form 4 explicitly notes that options with different terms are not included in this report. The transaction focuses on a specific grant of 20,000 employee stock options and does not consolidate or restate any other option awards with different terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 09:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Kevin Daniel

(Last) (First) (Middle)

660 MAIN STREET

FIRST FLOOR

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$0.9	03/04/2026		A		20,000		(1)	03/04/2036	Common Stock	20,000	$0	20,000(2)	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments beginning on April 4, 2026.

2. Options with different terms are not included.

	/s/ Daniel Hakansson, Attorney-in-fact for Kevin D. Weber	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.